Table 4.

Expression of TGF-βRII and pSmad2 in association with breast cancer disease-free survival, Shanghai Breast Cancer Study, Phase II

	No. of Cases	No. of Events	%	5-yr DFS	HR (95% CI)c	Pc	HR (95% CI)d	Pd	HR (95% CI)e	Pe
	All patients
pSmad2 intensity
0–2	457	62	13.6	0.86	reference		reference		reference
3	498	96	19.3	0.80	1.48 (1.07–2.04)	0.02	1.49 (1.07–2.06)	0.02	1.40 (1.00–1.94)	0.04
TGFβRII intensity
0–2	495	89	18.0	0.81	reference		reference		reference
3	460	69	15.0	0.85	0.81 (0.59–1.11)	0.19	0.86 (0.63–1.19)	0.37	0.87 (0.64–1.20)	0.35
TGFβRII pattern
1a	159	17	10.7	0.90	reference		reference		reference
2b	796	141	17.7	0.82	1.80 (1.08–3.00)	0.02	1.70 (1.02–2.83)	0.04	1.65 (0.99–2.76)	0.07
	Patients with ER-positive Breast Cancer
pSmad2 intensity
0–2	293	35	11.9	0.88	reference		reference		reference
3	311	55	17.7	0.82	1.53(1.00–2.33)	0.05	1.57 (1.02–2.44)	0.04	1.48 (0.96–2.30)	0.08
TGFβRII intensity
0–2	308	55	17.9	0.81	reference		reference		reference
3	296	35	11.8	0.89	0.65 (0.42–0.98)	0.04	0.71 (0.46–1.10)	0.21	0.71 (0.46–1.11)	0.12
TGFβRII pattern
1a	111	11	9.9	0.90	reference		reference		reference
2b	493	79	16.0	0.84	1.80 (0.95–3.40)	0.07	1.59 (0.83–3.03)	0.16	1.45 (0.76–2.78)	0.28
	Patients with ER-negative Breast Cancer
pSmad2 intensity
0–2	163	26	15.9	0.83	reference		reference		reference
3	185	41	22.2	0.76	1.47(0.89–2.42)	0.13	1.31 (0.79–2.18)	0.30	1.27 (0.76–2.13)	0.36
TGFβRII intensity
0–2	186	33	17.7	0.81	reference		reference		reference
3	162	34	21.0	0.78	1.15 (0.71–1.87)	0.04	1.13 (0.69–1.84)	0.62	1.10 (0.67–1.80)	0.70
TGFβRII pattern
1a	47	6	12.8	0.88	reference		reference		reference
2b	301	61	20.3	0.78	1.63 (0.70–3.79)	0.25	1.80 (0.76–4.25)	0.18	1.70 (0.71–4.04)	0.23

^aMembranous predominant

^bCytoplasmic or membranous cytoplasmic

^cAdjusted for age at diagnosis (continuous), BMI (continuous).

^dAdjusted for age at diagnosis (continuous), BMI (continuous), tumor size, grade, TNM stage, ER, PR.

^eAdjusted for age at diagnosis (continuous), BMI (continuous), tumor size, grade, TNM stage, ER, PR, radiotherapy, Chemotherapy, immunotherapy, and Tamoxifen use.